{"entity":{"id":"nct07629960","kind":"trial","name":"A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations","aka":[],"tldr":"A phase 1/2 trial of BLU-924 in non-small-cell lung cancer, colorectal cancer and pancreatic ductal adenocarcinoma, run by Blueprint Medicines Corporation, now recruiting.","summary":"A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations is a phase 1/2 interventional study registered as NCT07629960 by Blueprint Medicines Corporation, with 265 participants planned, started 2026-06-04 and due to reach its primary completion in 2029-09. Interventions recorded: BLU-924.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07629960","url":"https://clinicaltrials.gov/study/NCT07629960"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["nsclc","colorectal","pancreatic","metastatic-pdac"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["blueprint-medicines","sanofi"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07629960","phase":"1/2","setting":"A Phase 1/2, Open-Label, Dose-Escalation, Dose-Enrichment, and Dose-Expansion Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of BLU-924 (SAR449336) as Monotherapy and Combination Therapy in Participants With Advanced Pancreatic Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer Harboring KRAS Mutations","sponsor":"Blueprint Medicines Corporation","participation":[{"nct":"NCT07629960","source":"https://clinicaltrials.gov/study/NCT07629960","fetchedAt":"2026-10-07T16:55:51.217Z","studySha256":"fee6d95c52b58ea745e7662970615883c24968cecc251c996e10854a5df3e52b","overallStatus":"RECRUITING","lastUpdatePosted":"2026-09-21","leadSponsor":"Blueprint Medicines Corporation","collaboratorCount":1,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":265,"enrolmentType":"ESTIMATED","siteCount":16,"recruitingSiteCount":3,"countries":["Spain","United States"]}],"started":"2026-06-04","startedType":"actual","enrolled":265,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07629960/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"},{"id":"metastatic-pdac","kind":"cancer","name":"Metastatic pancreatic ductal adenocarcinoma","route":"/cancers/metastatic-pdac/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}],"company":[{"id":"blueprint-medicines","kind":"company","name":"Blueprint Medicines","route":"/companies/blueprint-medicines/"},{"id":"sanofi","kind":"company","name":"Sanofi","route":"/companies/sanofi/"}]}}